Is Microdosing a Placebo?

This review (2023) critically assesses the available evidence from dose-controlled studies investigating low doses of LSD and psilocybin. It proposes eight potential issues, such as small sample sizes, a limited number of controlled studies, and the possibility of selection bias, that challenge the claims that microdosing is predominantly a placebo effect. It suggests that it is currently inconclusive whether microdosing is merely a placebo.

Abstract of Is Microdosing a Placebo?

“Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. Here we step through all the available evidence from dose-controlled studies that have investigated the effects of low doses of LSD and psilocybin. We suggest eight reasons why current claims that microdosing is predominately a placebo are premature and possibly wrong: 1) there have been only a small number of controlled studies; 2) studies have had small sample sizes; 3) there is evidence of dose-dependent effects; 4) studies have only investigated the effects of a small number of doses; 5) the doses investigated may have been too small; 6) studies have looked only at non-clinical populations; 7) studies so far have been susceptible to selection bias; and 8) the measured impact of expectancy is small. Considering the available evidence, we conclude that it is not yet possible to determine whether microdosing is a placebo.”

Authors: Vince Polito & Paul Liknaitzky

Summary of Is Microdosing a Placebo?

Microdosing became popular around 2015, with thousands experimenting with this novel way of using psychedelics. There is still little scientific knowledge about the effects, mechanisms, or risks of regular use of psychedelic drugs at low doses.

Early microdosing studies reported positive effects on mental health, well-being, cognition, personality, changes in conscious state, and physiological changes.

To access this content, you must purchase one of the following memberships: Sprout Membership, Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Is Microdosing a Placebo?

https://doi.org/10.31234/osf.io/3ykst

Open Access | Google Scholar | Backup | 🕊

Cite this paper (APA)

Polito, V., & Liknaitzky, P. (2023, June 4). Is Microdosing a Placebo?. https://doi.org/10.31234/osf.io/3ykst

Study details

Compounds studied
Psilocybin LSD Placebo

Topics studied
Microdosing

Study characteristics
Literature Review

Authors

Authors associated with this publication with profiles on Blossom

Vince Polito
Vince Polito is a Senior Research Fellow in the School of Psychological Sciences, and a member of the Biomolecular Discovery Research Centre at Macquarie University.

Paul Liknaitzky
Dr Paul Liknaitzky, the Head of Clinical Psychedelic Research at Monash University, examines the mechanisms of mental illness and how to treat them. He is an investigator in several (of the first) psychedelic trials being conducted in Australia.

PDF of Is Microdosing a Placebo?

?>